行情

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ

实时行情|Nasdaq Last Sale

3.020
-0.080
-2.58%
盘后: 3.100 +0.08 +2.65% 16:17 01/24 EST
开盘
3.150
昨收
3.100
最高
3.200
最低
2.820
成交量
15.32万
成交额
--
52周最高
8.09
52周最低
2.710
市值
9,099.96万
市盈率(TTM)
-6.7516
分时
5日
1月
3月
1年
5年
Anixa says new protease inhibitor trumps main agent in Pfizer’s COVID-19 pill
Anixa Biosciences (NASDAQ:ANIX) has added ~6.5% in the pre-market after announcing that in early lab studies, a molecule developed by the company and partner MolGenie GmbH was more potent against COVID-19 than
Seekingalpha · 11小时前
Anixa Biosciences And MolGenie Announce Early Potency Analysis Of SARS-CoV-2 Protease Inhibitor
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today
Benzinga · 12小时前
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be consi...
PR Newswire · 12小时前
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 6天前
内部人士正在购买的 4 支低价股
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 01/10 14:41
Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which w...
PR Newswire · 2021/12/16 13:30
这就是为什么我们完全不关心 Anixa Biosciences（纳斯达克股票代码：ANIX）的现金消耗情况
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 2021/12/09 09:38
Anixa (ANIX) COVID 化合物证明对 Omicron 有效
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.
Zacks · 2021/12/08 12:47
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解ANIX最新的财务预测，通过ANIX每股收益，每股净资产，每股现金流等数据分析Anixa Biosciences Inc近期的经营情况，然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ANIX价格均价为11.00，最高价位11.00，最低价为11.00。
最高11.00
均价11.00
最低11.00
现价3.020
EPS
实际EPS
预期EPS
-0.11-0.08-0.06-0.03
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
机构持股
总机构数: 41
机构持股: 320.26万
持股比例: 10.63%
总股本: 3,013.23万
类型机构数股数
增持
8
30.21万
建仓
7
10.24万
减持
10
15.47万
平仓
4
2.42万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.12%
制药与医学研究
-0.55%
高管信息
Chairman/President/Chief Executive Officer/Director
Amit Kumar
Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Michael Catelani
Lead Director/Independent Director
Lewis Titterton
Independent Director
Arnold Baskies
Independent Director
Emily Gottschalk
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
ANIX 简况
Anixa Biosciences Inc是一家生物技术公司。该公司正在开发针对肿瘤和传染病的治疗方法和疫苗。该公司正在开发嵌合内分泌受体T细胞技术，一种专注于治疗卵巢癌的嵌合抗原受体T细胞（CAR-T）技术，以及靶向抑制某些病毒蛋白功能的COVID-19抗病毒候选药物。它还在开发针对三阴性乳腺癌（TNBC）（这是一种致命的乳腺癌）的疫苗，以及一种针对卵巢癌的疫苗。其子公司Certainty Therapeutics, Inc.（Certainty）正在开发针对癌症的免疫治疗药物。

微牛提供Anixa Biosciences Inc(NASDAQ-ANIX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ANIX股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ANIX股票基本功能。